Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

• DOI: 10.1086/656417
• Publication Date: 2010-09-09T15:50:51Z
• Authors: Hans‐Jürgen Stell...; Chloe Orkin; Jose Ramon Arribas; Juliet Compston; Jan Gerstoft; Eric Van Wijngaerden; Adriano Lazzarin; Giuliano Rizzardini; Herman G. Sprenger; John Lambert; Gunta Sture; David Leather; Sara Hughes; Patrizia Zucchi; Helen Pearce
• Keywords: Emtricitabine; Abacavir

Background. Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.